Prevalence of lupus nephritis in diagnosed patients of systemic lupus erythematosis (SLE) presenting to nephrology division, Khyber teaching hospital Peshawar

Zaryab Khan; Muhammad Awais; Waqar Ul Haq; Sana Arshad; Muneeb Aslam; Saba Waheed; Faizan Banaras

doi:10.53730/ijhs.v7nS1.14215

Authors

Zaryab Khan Internal Medicine Khyber Teaching Hospital, Peshawar Pakistan
Muhammad Awais Postgraduate Resident Internal Medicine, Khyber Teaching Hospital, Peshawar Pakistan
Waqar Ul Haq Postgraduate Resident Nephrology, Khyber Teaching Hospital, Peshawar Pakistan
Sana Arshad Ayub Teaching Hospital, Abbottabad Pakistan
Muneeb Aslam Mufti Mehmood Memorial Teaching Hospital, MMMTH/GMC-MTI, Dera Ismail Khan Pakistan
Saba Waheed Resident Medicine, Khyber Teaching Hospital, Peshawar Pakistan
Faizan Banaras
faizanbanaras958@gmail.com
Postgraduate Resident Nephrology, Khyber Teaching Hospital Peshawar, Pakistan

Keywords:

lupus nephritis, systemic lupus erythematosis, prevalence

Abstract

Objective: To determine the prevalence of lupus nephritis in patients diagnosed with systemic lupus erythematosis (SLE). Settings: This observational study was conducted at the department of nephrology, Khyber Teaching Hospital, Peshawar Pakistan. Participants were enrolled from 1^st January 2022 to 31^st March 2022. Materials and methods: Patients diagnosed with SLE were enrolled. SLE was confirmed based American college of rheumatology criteria for SLE (positive ANA ≥1:80 and clinical score 10 or more). Lupus nephritis was confirmed when serum creatinine was more than 1.5mg/dl and urinary protein loss more than 0.5gm/day. Results: A total of 109 patients were enrolled. Mean age of the patients was 29.80 ± 5.245 years. 68 participants (62.4%) were female. Lupus nephritis was observed in 56 patients (51.4%). Correlation of lupus nephritis showed significant association with age and gender of the patient. Conclusion: Lupus nephritis is fairly common in patients with SLE in our population. Young female patients are more likely having it.

Downloads

Download data is not yet available.

References

Pons-Estel GJ, Ugarte-Gil MF, Alarcon GS. Epidemiology of systemic lupus erythematosus. Expert Rev Clin Immunol. 2017;13:799–814.

Feldman CH, Hiraki LT, Liu J. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004. Arthritis Rheum. 2013;65:753–63.

Izmirly PM. Prevalence of systemic lupus erythematosus in the United States: estimates from a meta-analysis of the centers for disease control and prevention national lupus registries. Arthritis Rheumatol. 2021;73(6):991–6.

Li S, Gong T, Peng Y. Prevalence and incidence of systemic lupus erythematosus and associated outcomes in the 2009–2016 US Medicare population. Lupus. 2020;29:15–26

Gandhi K, Alemao E, Kawabata H. Prevalence of systemic lupus erythematosus and lupus nephritis in the United States: analysis of commercial and public insurance billing data. Arthritis Rheum. 2013;65(S10):S457.

Wallace DJ, Hahn B, editors. Dubois' lupus erythematosus. Lippincott Williams & Wilkins; 2007.

Costenbader KH, Desai A, Alarcón GS, Hiraki LT, Shaykevich T. Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum. 2011;63(6):1681-8.

Croca SC, Rodrigues T, Isenberg DA. Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology (Oxford). 2011;50(8):1424-30.

Houssiau FA, Vasconcelos C, D'Cruz D, Sebastiani GD, mmunosuppressive therapy in lupus nephritis: the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum. 2002 Aug;46(8):2121-31.

Houssiau FA, Vasconcelos C. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis. 2010;69(1):61-4

Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol. 2009;20(5):1103-12.

Thumboo J, Uramoto K, O'Fallon WM. A comparative study of the clinical manifestations of systemic lupus erythematosus in Caucasians in Rochester, Minnesota, and Chinese in Singapore, from 1992 to 2010. Arthritis Rheum. 2012;45(6):494-500. doi: 10.1002/1529-0131(200112)45:6<494::aid-art374>3.0.co;2-m. PMID: 11762683.

Uthman IW, Muffarij AA, Mudawar WA, Nasr FW, Masri AF. Lupus nephritis in Lebanon. Lupus. 2011;10(5):378-81.

Rabbani MA, Shah SM, Ahmed A. Cutaneous manifestations of systemic lupus erythematosus in Pakistani patients. J Pak Med Assoc. 2009;53(11):539-41.

Sulaiman K, Sohail KS, Sheikh AA, Raza F, Shahzad F, Siddique A, Shakir T, Rabbani F. Clinical spectrum of systemic lupus erythematosus at the Aga Khan University Hospital. J Pak Med Assoc. 2000;50(10):364-7.

Tektonidou MG, Dasgupta A, Ward MM. Risk of end‐stage renal disease in patients with lupus nephritis, 1971–2015: a systematic review and Bayesian meta‐analysis. Arthritis & rheumatology. 2016;68(6):1432-41.

Somers EC, Marder W, Cagnoli P, Lewis EE, DeGuire P. Population‐based incidence and prevalence of systemic lupus erythematosus: the Michigan Lupus Epidemiology and Surveillance program. Arthritis & rheumatology. 2014;66(2):369-78.

Feldman CH, Hiraki LT, Liu J, Fischer MA, Solomon DH, Alarcón GS, Winkelmayer WC, Costenbader KH. Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000–2004. Arthritis & Rheumatism. 2013;65(3):753-63.

Rabbani MA, Habib HB, Islam M, Ahmad B, Majid S, Saeed W, Shah SM, Ahmad A. Survival analysis and prognostic indicators of systemic lupus erythematosus in Pakistani patients. Lupus. 2009;18(9):848-55.